Ankylosing Spondylitis: Causes, Symptoms & Treatment

Understanding Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that primarily affects the spine and sacroiliac joints. This progressive condition causes inflammation of the spinal joints (spondylitis) and can eventually lead to spinal fusion, where vertebrae fuse together and the spine becomes rigid. The name “ankylosing” refers to the fusion process, while “spondylitis” describes the spinal inflammation. AS is part of a broader group of inflammatory arthropathies known as spondyloarthritis (SpA).

Unlike rheumatoid arthritis, ankylosing spondylitis was historically classified as a seronegative spondyloarthropathy, meaning patients typically test negative for rheumatoid factor. However, most people with AS carry the HLA-B27 genetic marker. The condition typically begins in early adulthood, though it can develop at any age, and affects men more frequently than women.

Causes and Risk Factors

The exact cause of ankylosing spondylitis remains not fully understood, but genetic predisposition plays a significant role in its development. The strongest genetic factor associated with AS is the presence of the HLA-B27 gene. Individuals who carry this genetic marker have a substantially higher risk of developing the condition, though not everyone with HLA-B27 develops AS.

Environmental and immunological factors likely trigger the disease in genetically susceptible individuals. Researchers believe that bacterial infections may act as environmental triggers in some cases. Family history is another important risk factor; having a close relative with AS increases the likelihood of developing the condition. Men are approximately two to three times more likely to develop ankylosing spondylitis than women, though women may experience delayed diagnosis due to different symptom presentations.

Recognizing Symptoms

The symptoms of ankylosing spondylitis typically develop gradually and vary in severity among individuals. Early recognition of symptoms is crucial for timely intervention and disease management.

Early Symptoms

The most common initial symptoms include low back pain and stiffness, particularly affecting the sacroiliac joints where the spine connects to the pelvis. Morning stiffness is a hallmark feature of AS, often lasting several hours after waking. This stiffness improves with movement and activity rather than with rest, distinguishing it from mechanical back pain. Pain and stiffness may worsen after periods of inactivity and improve with gentle movement or exercise.

Progressive Symptoms

As the disease progresses, individuals may experience neck pain and reduced spinal mobility. Fatigue is common and can significantly impact daily functioning and quality of life. Some patients develop pain in the buttocks and upper thighs. Over time, the inflammation can spread to other parts of the spine, causing increasing stiffness and reduced flexibility. In advanced cases, spinal fusion can develop, potentially affecting posture and the ability to look upward.

Extra-Articular Manifestations

Beyond spinal involvement, ankylosing spondylitis can affect other body systems. Enthesitis, inflammation at the sites where tendons and ligaments attach to bones, commonly occurs in the heels and other areas. Peripheral arthritis, affecting larger joints like the hips, knees, and shoulders, develops in approximately 30% of AS patients. Eye inflammation (uveitis) occurs in about 30% of cases and requires prompt treatment to prevent vision problems. Inflammatory bowel disease may accompany AS in some patients.

Diagnosis and Evaluation

Diagnosing ankylosing spondylitis involves a comprehensive approach combining clinical assessment, imaging studies, and laboratory tests. Early diagnosis is critical because appropriate treatment initiated early can help preserve spinal mobility and prevent long-term complications.

Clinical Assessment

Rheumatologists evaluate the patient’s medical history, including the onset, duration, and pattern of symptoms. The presence of morning stiffness that improves with activity is a significant diagnostic clue. Physical examination includes assessing spinal range of motion through tests like the Schober test, which measures lumbar spine flexibility. Physicians also examine for signs of enthesitis and peripheral joint involvement.

Laboratory Tests

Blood tests play an important role in AS diagnosis. The HLA-B27 test is frequently positive in AS patients, though its presence alone is not diagnostic. Elevated inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), indicate active inflammation. These markers help confirm the inflammatory nature of the condition and serve as baseline measurements for monitoring treatment response.

Imaging Studies

X-rays are essential for detecting structural changes associated with AS. Early signs include inflammation and erosion of the sacroiliac joints. As the disease progresses, the characteristic “bamboo spine” appearance develops, showing fusion of the vertebral bodies. Magnetic resonance imaging (MRI) can detect early inflammatory changes in the sacroiliac joints and spine before they appear on X-rays, making it valuable for early diagnosis.

Treatment Approaches

While there is currently no cure for ankylosing spondylitis, modern treatments can effectively reduce pain, inflammation, and stiffness while slowing disease progression. Treatment success depends on early diagnosis, consistent management, and individualized approaches tailored to each patient’s needs.

Physical Therapy and Exercise

Physical therapy and regular exercise form the foundation of AS treatment and are essential for all patients regardless of disease severity. Structured exercise programs improve spinal mobility, strengthen muscles supporting the spine, and maintain flexibility. Swimming, stretching, and low-impact aerobic activities are particularly beneficial. Posture exercises help prevent the forward-bending deformity that can develop in advanced AS. Heat therapy, including hot baths and warm showers, can provide symptomatic relief by reducing stiffness and pain. Patients should maintain consistent exercise routines to achieve optimal outcomes and prevent disease progression.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs are typically the first-line pharmacological treatment for ankylosing spondylitis. Common NSAIDs used include indomethacin, naproxen, diclofenac, and celecoxib (a COX-2 inhibitor). These medications reduce inflammation, decrease pain, and improve stiffness. NSAIDs are most effective when used at near-maximum recommended doses. While NSAIDs do not slow the underlying disease progression or prevent spinal fusion, they provide significant symptomatic relief. For some patients with milder disease, NSAIDs combined with physical therapy may be sufficient for disease management. Doctors work to find the most effective NSAID at the lowest possible dose, regularly monitoring effectiveness and side effects.

Paracetamol and Stronger Analgesics

For patients who cannot tolerate NSAIDs or need additional pain relief, paracetamol serves as an alternative, though it lacks anti-inflammatory properties. Stronger painkillers like codeine may be prescribed when necessary, though these carry risks of side effects including nausea, vomiting, constipation, and drowsiness. These medications are used judiciously and typically for short-term relief rather than long-term management.

Biologic Therapies

Biologic medications have revolutionized AS treatment, providing dramatic improvements in symptoms and function for many patients. These advanced therapies target specific components of the immune system responsible for inflammation.

Anti-TNF Medications: These represent the most established biologic therapy for AS. TNF (tumor necrosis factor) is a key inflammatory protein, and blocking it significantly reduces inflammation and improves outcomes. Anti-TNF agents approved for AS include infliximab (administered intravenously), and self-injected medications such as etanercept, adalimumab, golimumab, and certolizumab pegol. Clinical trials demonstrate that anti-TNF medications reduce inflammatory back pain, improve physical function, decrease fatigue, and enhance quality of life. However, they require careful monitoring due to potential immunosuppressive effects.

IL-17 Inhibitors: Newer biologic therapies that block interleukin-17, a pro-inflammatory cytokine, have gained FDA approval for AS treatment. Secukinumab and ixekizumab are monoclonal antibodies administered by self-injection. These medications provide an effective alternative for patients who do not respond adequately to anti-TNF drugs or as primary biologic therapy.

JAK Inhibitors

Janus kinase (JAK) inhibitors represent another class of medications approved for AS. Tofacitinib and upadacitinib are oral medications that work by blocking enzymes the immune system uses to trigger inflammation. JAK inhibitors offer a convenient oral option for patients who prefer not to receive injections and may be particularly beneficial for those who do not respond to or cannot tolerate anti-TNF therapy.

Corticosteroid Injections

Local corticosteroid injections provide targeted anti-inflammatory effects for specific inflamed joints. These injections can be administered directly into affected joints, such as the sacroiliac joints or peripheral joints like the knees and hips. Corticosteroids have powerful anti-inflammatory properties and provide prompt symptom relief. However, due to potential side effects with repeated use, injections are typically limited to no more than three times per year in the same joint, with at least three months between injections.

Other Treatment Considerations

Disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine and methotrexate may be effective for managing peripheral arthritis and extra-articular manifestations. Surgery is occasionally considered for patients with severe, disabling disease or significant spinal deformities, though it is not commonly required. Management should be individualized based on disease severity, pattern of involvement, patient preferences, and response to initial therapies.

Disease Prognosis and Long-Term Outlook

The long-term prognosis for ankylosing spondylitis varies significantly among patients. Some individuals experience progressive spinal fusion leading to complete ankylosis, while others experience intermittent flares alternating with periods of remission or low disease activity. Factors affecting prognosis include disease severity at onset, presence of peripheral arthritis, genetic factors, and adherence to treatment regimens.

With modern treatment approaches, most patients can maintain good functional capacity and quality of life. Early diagnosis and aggressive treatment significantly improve outcomes by preserving spinal mobility and preventing permanent deformities. The primary goal of long-term AS management is to maintain physical functioning, minimize work absence, reduce pain and stiffness, and preserve quality of life. Regular follow-up with rheumatologists, consistent adherence to exercise programs, and appropriate medication adjustments as needed help achieve these goals.

Frequently Asked Questions

Q: Is ankylosing spondylitis curable?

A: Currently, there is no cure for ankylosing spondylitis. However, modern treatments are highly effective at reducing symptoms, controlling inflammation, and slowing disease progression. Many patients achieve significant functional improvement and can maintain active lifestyles with appropriate treatment.

Q: How is ankylosing spondylitis different from regular back pain?

A: AS-related back pain is inflammatory rather than mechanical, typically worsens with rest and improves with activity, and is accompanied by morning stiffness lasting several hours. Regular back pain usually worsens with activity and improves with rest.

Q: Can ankylosing spondylitis affect people other than the spine?

A: Yes, AS can affect peripheral joints, entheses (tendon and ligament attachment sites), and other organs including the eyes, potentially causing uveitis. Some patients also develop inflammatory bowel conditions.

Q: What is the role of exercise in managing ankylosing spondylitis?

A: Exercise is fundamental to AS management. Regular physical activity improves spinal mobility, strengthens supporting muscles, maintains flexibility, and helps prevent disease progression and spinal deformities. Consistent exercise combined with medication provides optimal outcomes.

Q: How long does it take to see improvement with treatment?

A: Physical therapy is a gradual process requiring weeks to months for noticeable improvement. Medications take varying amounts of time to take effect; NSAIDs may provide relief within days, while biologic therapies typically require weeks to months for maximum benefit.

Q: Are there lifestyle modifications that help manage ankylosing spondylitis?

A: Yes, maintaining proper posture, practicing regular stretching and strengthening exercises, applying heat therapy, managing stress, maintaining a healthy weight, and avoiding smoking all support AS management and help preserve spinal function.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb